References
- Iqbal HMN, Romero-Castillo KD, Bilal M, Parra-Saldivar R. The emergence of novel-coronavirus and its replication cycle-an overview. J Pure Appl Microbiol. 2020;14(1):13–16. Article: 6146. doi:https://doi.org/10.22207/JPAM.14.1.03.
- Saif LJ. Vaccines for COVID-19: perspectives, prospects, and challenges based on candidate SARS, MERS, and animal coronavirus vaccines. EuroMed J. 2020. doi:https://doi.org/10.33590/emj/200324.
- WHO, Situation report – 92. [accessed 2020 April 22]. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200421-sitrep-92-covid-19.pdf?sfvrsn=38e6b06d_4.
- Gorbalenya AE, Baker SC, Baric R, Groot RJD, Drosten C, Gulyaeva AA, Penzar D. Severe acute respiratory syndrome-related coronavirus: the species and its viruses–a statement of the coronavirus study group. BioRxiv. 2020. doi:https://doi.org/10.1101/2020.02.07.937862v1.
- Kupferschmidt K, Cohen J. Will novel virus go pandemic or be contained? Science. 2020;367(6478):610–11. doi:https://doi.org/10.1126/science.367.6478.610.
- Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Chen HD. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–73. doi:https://doi.org/10.1038/s41586-020-2012-7.
- Bilal M, Nazir MS, Parra-Saldivar R, Iqbal HMN. 2019-nCoV/COVID-19 - approaches to viral vaccine development and preventive measures. J Pure Appl Microbiol. 2020;14(1):25–29. Article: 6168. doi:https://doi.org/10.22207/JPAM.14.1.05.
- Enjuanes L, DeDiego ML, Álvarez E, Deming D, Sheahan T, Baric R. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res. 2008;133(1):45–62. doi:https://doi.org/10.1016/j.virusres.2007.01.021.
- Roper RL, Rehm KE. SARS vaccines: where are we? Expert Rev Vaccines. 2009;8(7):887–98. doi:https://doi.org/10.1586/erv.09.43.
- Rauch S, Jasny E, Schmidt KE, Petsch B. New vaccine technologies to combat outbreak situations. Front Immunol. 2018;9:1963. doi:https://doi.org/10.3389/fimmu.2018.01963.
- Ströher U, DiCaro A, Li Y, Strong JE, Aoki F, Plummer F, Feldmann H. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-α. J Infect Dis. 2004;189(7):1164–67. doi:https://doi.org/10.1086/382597.
- Zorzitto J, Galligan CL, Ueng JJ, Fish EN. Characterization of the anti-viral effects of interferon-α against a SARS-like coronoavirus infection in vitro. Cell Res. 2006;16(2):220–29. doi:https://doi.org/10.1038/sj.cr.7310030.
- Haagmans BL, Kuiken T, Martina BE, Fouchier RA, Rimmelzwaan GF, Van Amerongen G, Tashiro M. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med. 2004;10(3):290–93. doi:https://doi.org/10.1038/nm1001.
- Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, Kain KC. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA. 2003;290(24):3222–28. doi:https://doi.org/10.1001/jama.290.24.3222.
- Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Brun S. Lopinavir–ritonavir versus nelfinavir for the initial treatment of HIV infection. New Engl J Med. 2002;346(26):2039–46. doi:https://doi.org/10.1056/NEJMoa012354.
- Pulido F, Arribas JR, Delgado R, Cabrero E, González-García J, Pérez-Elias MJ, Rubio R. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS. 2008;22(2):F1–F9. doi:https://doi.org/10.1097/QAD.0b013e3282f4243b.
- Lin S, Shen R, Guo X. Molecular modeling evaluation of the binding abilities of ritonavir and lopinavir to wuhan pneumonia coronavirus proteases. BioRxiv. 2020. doi:https://doi.org/10.1101/2020.01.31.929695.
- Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, Peiris JSM. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252–56. doi:https://doi.org/10.1136/thorax.2003.012658.
- Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327. doi:https://doi.org/10.1038/nrd.2015.37.
- Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, Spahn JE. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):1–14. doi:https://doi.org/10.1038/s41467-019-13940-6.
- Khamitov RA, Loginova S, Shchukina VN, Borisevich SV, Maksimov VA, Shuster AM. Anti-viral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Voprosy Virusol. 2008;53:9–13.
- Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trend. 2020;14:64–68. doi:https://doi.org/10.5582/bst.2020.01030.
- Zhang J, Zhou L, Yang Y, Peng W, Wang W, Chen X. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet Respir Med. 2020;8(3):e11–e12. doi:https://doi.org/10.1016/S2213-2600(20)30071-0.
- Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systemic review. J Med Virol. 2020;92:479–90. doi:https://doi.org/10.1002/jmv.25707.
- Zhang N, Wang L, Deng X, Liang R, Su M, He C, Du L. Recent advances in the detection of respiratory virus infection in humans. J Med Virol. 2020;92(4):408–17. doi:https://doi.org/10.1002/jmv.25674.
- Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, Sheng JF. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. Bmj. 2020;368:m606. doi:https://doi.org/10.1136/bmj.m606.
- Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Ray AS. Coronavirus susceptibility to the anti-viral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018;9(2):e00221–18. doi:https://doi.org/10.1128/mBio.00221-18.
- de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, Feldmann H. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci. 2020;117(12):6771–76. doi:https://doi.org/10.1073/pnas.1922083117.
- Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Diaz G. First case of 2019 novel coronavirus in the United States. New Engl J Med. 2020;382:929–36. doi:https://doi.org/10.1056/NEJMoa2001191.
- Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspective. Int J Antimicrob Agents. 2020;55:105951. doi:https://doi.org/10.1016/j.ijantimicag.2020.105951.
- Li K, Li Z, Wohlford-Lenane C, Meyerholz DK, Channappanavar R, An D, He B. Single-dose, intranasal immunization with recombinant parainfluenza virus 5 expressing middle east respiratory syndrome coronavirus (MERS-CoV) spike protein protects mice from fatal MERS-CoV infection. mBio. 2020;11(2):e00554–20. doi:https://doi.org/10.1128/mBio.00554-20.
- Park JY, Jeong HJ, Kim JH, Kim YM, Park SJ, Kim D, Ryu YB. Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute respiratory syndrome coronavirus. Biol Pharm Bull. 2012;35:2036–42. doi:https://doi.org/10.1248/bpb.b12-00623.
- Chen L, Gui C, Luo X, Yang Q, Günther S, Scandella E, Chen J. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J Virol. 2005;79(11):7095–103. doi:https://doi.org/10.1128/JVI.79.11.7095-7103.2005.
- Panche AN, Diwan AD, Chandra SR. Flavonoids: an overview. J Nutr Sci. 2016;5:e47. doi:https://doi.org/10.1017/jns.2016.41.
- Jo S, Kim S, Shin DH, Kim MS. Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem. 2020;35(1):145–51. doi:https://doi.org/10.1080/14756366.2019.1690480.
- Ryu YB, Jeong HJ, Kim JH, Kim YM, Park JY, Kim D, Rho MC. Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition. Bioorg Med Chem. 2010;18(22):7940–47. doi:https://doi.org/10.1016/j.bmc.2010.09.035.
- Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Choe H. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–54. doi:https://doi.org/10.1038/nature02145.
- Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci. 2004;101(12):4240–45. doi:https://doi.org/10.1073/pnas.0306446101.
- Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asia Pac J Allergy Immunol. 2020;38(1):10–18. doi:https://doi.org/10.12932/AP-200220-0773.
- Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, Anderson LJ. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci. 2004;101(8):2536–41. doi:https://doi.org/10.1073/pnas.0307140101.
- Yan Y, Zou Z, Sun Y, Li X, Xu KF, Wei Y, Jiang C. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 2013;23(2):300–02. doi:https://doi.org/10.1038/cr.2012.165.
- Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Nichol ST. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2(1):69. doi:https://doi.org/10.1186/1743-422X-2-69.
- Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71. doi:https://doi.org/10.1038/s41422-020-0282-0.
- Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res. 2020;177:104762. doi:https://doi.org/10.1016/j.antiviral.2020.104762.
- Alves DS, Pérez-Fons L, Estepa A, Micol V. Membrane-related effects underlying the biological activity of the anthraquinones emodin and barbaloin. Biochem Pharmacol. 2004;68(3):549–61. doi:https://doi.org/10.1016/j.bcp.2004.04.012.
- Ho TY, Wu SL, Chen JC, Li CC, Hsiang CY. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res. 2007;74(2):92–101. doi:https://doi.org/10.1016/j.antiviral.2006.04.014.
- Zhang XW, Yap YL. Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs. Bioorg Med Chem. 2004;12(10):2517–21. doi:https://doi.org/10.1016/j.bmc.2004.03.035.
- Koch T, Dahlke C, Fathi A, Kupke A, Krähling V, Okba NM, Hesterkamp T. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. The Lancet Infect Dis. 2020;20:827–38. doi:https://doi.org/10.1016/S1473-3099(20)30248-6.
- Liu R, Wang J, Shao Y, Wang X, Zhang H, Shuai L, Bu Z. A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization. Antiviral Res. 2018;150:30–38. doi:https://doi.org/10.1016/j.antiviral.2017.12.007.
- Chi H, Zheng X, Wang X, Wang C, Wang H, Gai W, Xia X. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice. Vaccine. 2017;35(16):2069–75. doi:https://doi.org/10.1016/j.vaccine.2017.02.063.
- Hu H, Huang X, Tao L, Huang Y, Cui BA, Wang H. Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administrated with different routes in mouse model. Vaccine. 2009;27(11):1758–63. doi:https://doi.org/10.1016/j.vaccine.2009.01.021.
- Hu H, Lu X, Tao L, Bai B, Zhang Z, Chen Y, Wang H. Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice. Clin Vaccine Immunol. 2007;14(7):894–901. doi:https://doi.org/10.1128/CVI.00019-07.
- Shi SQ, Peng JP, Li YC, Qin C, Liang GD, Xu L, Sun QH. The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization. Mol Immunol. 2006;43(11):1791–98. doi:https://doi.org/10.1016/j.molimm.2005.11.005.
- Woo PC, Lau SK, Tsoi HW, Chen ZW, Wong BH, Zhang L, Chan KH. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine. 2005;23(42):4959–68. doi:https://doi.org/10.1016/j.vaccine.2005.05.023.
- Zhao P, Cao J, Zhao LJ, Qin ZL, Ke JS, Pan W, Qi ZT. Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine. Virology. 2005;331(1):128–35. doi:https://doi.org/10.1016/j.virol.2004.10.016.
- Saif LJ. Coronaviruses of domestic livestock and poultry: interspecies transmission, pathogenesis, and immunity. In: Perlman S, Gallagher T, Snijder EJ, editors. Nidoviruses. Washington (DC): ASM Press; 2008. p. 279–98.
- Jordan B. Vaccination against infectious bronchitis virus: a continuous challenge. Vet Microbiol. 2017;206:137–43. doi:https://doi.org/10.1016/j.vetmic.2017.01.002.
- Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, Albaiu D. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci. 2020;6:315–31. doi:https://doi.org/10.1021/acscentsci.0c00272.
- Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, Collins PL. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci. 2004;101(26):9804–09. doi:https://doi.org/10.1073/pnas.0403492101.
- Schindewolf C, Menachery VD. Middle East respiratory syndrome vaccine candidates: cautious optimism. Viruses. 2019;11(1):74. doi:https://doi.org/10.3390/v11010074.
- Mark D. Live attenuated Coronavirus vaccines. US Patent. 2020; US20060039926A1. 2006 Feb 23 [accessed 2020 June 14]. https://patentimages.storage.googleapis.com/b5/d4/fb/5d1a763f553801/US20060039926A1.pdf.
- WHO, COVID-2019 (World Health Organization). Coronavirus disease (COVID-2019) situation reports. 2020 [accessed 2020 April 22]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
- Smith G, Liu Y, Massare M. Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods. WO2015042373A1. 2015 Mar 26 [accessed 2020 June 14]. https://patentimages.storage.googleapis.com/37/79/44/80efd21dd76bd5/WO2015042373A1.pdf.
- Novavax press release on 2020 Feb 26. http://ir.novavax.com/news-releases/news-release-details/novavax-advances-developmentnovel-covid-19-vaccine.
- Wu T-C, Hung C-F, Kim TW DNA vaccines targeting antigens of the severe acute respiratory syndrome coronavirus (SARS-CoV). WO2005081716A3. 2005 Sept 9 [accessed 2020 June 14]. https://patentimages.storage.googleapis.com/75/0f/29/7245823f01f88f/WO2005081716A3.pdf.
- Weiner DB, Muthumani K, Sardesai NY. Mers-cov vaccine. WO2015081155A1. 2015 June 4 [accessed 2020 June 14]. https://patentimages.storage.googleapis.com/76/e3/5b/8215a5a09e4fd0/WO2015081155A1.pdf.
- Ciaramella G, Himansu S. Respiratory virus vaccines. WO2017070626A2. 2017 Apr 27 [accessed 2020 June 14]. https://patentimages.storage.googleapis.com/e7/f9/bb/eb3ec1e7790856/WO2017070626A2.pdf.
- Moderna press release on 2020 Feb 24. https://investors.modernatx.com/news-releases/news-release-details/moderna-shipsmrna-vaccine-against-novel-coronavirus-mrna-1273.
- Baras B, Callendret B, Escriou N, Lorin V, Marianneau P, Werf SVD, Wettendorff MAC. Vaccine. WO2010063685A1. 2010 June 10 [accessed 2020 June 14]. https://patentimages.storage.googleapis.com/3e/71/12/465a5cf4aa8d22/WO2010063685A1.pdf.
- Humphreys R, Xu M. Ii-key/antigenic epitope hybrid peptide vaccines. US20060002947A1. 2006 Jan 5 [accessed 2020 June 14]. https://patentimages.storage.googleapis.com/a9/80/5b/fb4e65c96b7369/US20060002947A1.pdf.
- Generex press release on 2020 Feb 27. https://storage.googleapis.com/wzukusers/user-26831283/documents/5e57ed391b286sVf68Kq/PR_Generex_Coronavirus_Update_2_27_2020.pdf.
- Woelfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Mueller MA, Bleicker T. Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster. MedRxiv. 2020. doi:https://doi.org/10.1101/2020.03.05.20030502.
- Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL, Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44–46. doi:https://doi.org/10.1007/s10096-004-1271-9.
- Ng OW, Tan YJ. Understanding bat SARS-like coronaviruses for the preparation of future coronavirus outbreaks—Implications for coronavirus vaccine development. Hum Vaccines Immunother. 2017;13(1):186–89. doi:https://doi.org/10.1080/21645515.2016.1228500.